Intragraft verapamil is effective in treating no-reflow during saphenous vein graft (SVG) percutaneous coronary intervention (PCI). In this study, we assessed the use of intragraft verapamil given pre-PCI to prevent no-reflow.
Pretreatment with intragraft verapamil prior to percutaneous coronary intervention of saphenous vein graft lesions: results of the randomized, controlled vasodilator prevention on no-reflow (VAPOR) trial.
University of California at San Francisco Medical Center, Division of Cardiology, 505 Parnassus Avenue, Box 0124, San Francisco, CA 94143-0124, USA. andrewm@itsa.ucsf.edu